X
Novartis/Amgen migraine jab works in tough-to-treat patients
https://pharmaphorum.com/news/novartis-amgen-migraine-jab-works-tough-treat-patients/
Teva
FDA rejects Teva/Celltrion biosimilars
Regulator cites issues with manufacturing plant
Sosei see Teva pipeline cull as an opportunity
Troubled generics giant Teva is continuing the heavy pruning of its business and has cut a novel migraine drug from its pipeline.
Novartis/Amgen migraine drug reduces attacks after others fail
Aimovig notches up another late-stage trial success
NHS funding for five MS drugs under threat
NICE calls for further discounts on beta-interferons and Copaxone
GSK’s Nucala gains US use in rare autoimmune disease
IL-5 drug approved in EGPA
